Literature DB >> 30836144

Loss of human arylamine N-acetyltransferase I regulates mitochondrial function by inhibition of the pyruvate dehydrogenase complex.

Lili Wang1, Rodney F Minchin2, Patricia J Essebier1, Neville J Butcher1.   

Abstract

Human arylamine N-acetyltransferase 1 (NAT1) has been widely reported to affect cancer cell growth and survival and recent studies suggest it may alter cell metabolism. In this study, the effects of NAT1 deletion on mitochondrial function was examined in 2 human cell lines, breast carcinoma MDA-MB-231 and colon carcinoma HT-29 cells. Using a Seahorse XFe96 Flux Analyzer, NAT1 deletion was shown to decrease oxidative phosphorylation with a significant loss in respiratory reserve capacity in both cell lines. There also was a decrease in glycolysis without a change in glucose uptake. The changes in mitochondrial function was due to a decrease in pyruvate dehydrogenase activity, which could be reversed with the pyruvate dehydrogenase kinase inhibitor dichloroacetate. In the MDA-MB-231 and HT-29 cells, pyruvate dehydrogenase activity was attenuated either by an increase in phosphorylation or a decrease in total protein expression. These results may help explain some of the cellular events that have been reported recently in cell and animal models of NAT1 deficiency.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arylamine N-acetyltransferase; Mitochondria; Pyruvate dehydrogenase

Mesh:

Substances:

Year:  2019        PMID: 30836144     DOI: 10.1016/j.biocel.2019.03.002

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  5 in total

1.  Deletion of arylamine N-acetyltransferase 1 in MDA-MB-231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis.

Authors:  Mark A Doll; Andrew R Ray; Raúl A Salazar-González; Parag P Shah; Alexis A Vega; Sophia M Sears; Austin M Krueger; Kyung U Hong; Levi J Beverly; David W Hein
Journal:  Mol Carcinog       Date:  2022-02-08       Impact factor: 5.139

2.  Acetylator Genotype-Dependent Dyslipidemia in Rats Congenic for N-Acetyltransferase 2.

Authors:  Kyung U Hong; Mark A Doll; Angeliki Lykoudi; Raúl A Salazar-González; Mariam R Habil; Kennedy M Walls; Alaa F Bakr; Smita S Ghare; Shirish S Barve; Gavin E Arteel; David W Hein
Journal:  Toxicol Rep       Date:  2020-09-28

3.  N-Acetyltransferase 1 Knockout Elevates Acetyl Coenzyme A Levels and Reduces Anchorage-Independent Growth in Human Breast Cancer Cell Lines.

Authors:  Marcus W Stepp; Raúl A Salazar-González; Kyung U Hong; Mark A Doll; David W Hein
Journal:  J Oncol       Date:  2019-08-20       Impact factor: 4.375

4.  Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.

Authors:  Courtney E McAleese; Neville J Butcher; Rodney F Minchin
Journal:  Breast Cancer Res Treat       Date:  2022-08-02       Impact factor: 4.624

5.  Proteomic analysis of arylamine N-acetyltransferase 1 knockout breast cancer cells: Implications in immune evasion and mitochondrial biogenesis.

Authors:  Kyung U Hong; Jonathan Q Gardner; Mark A Doll; Marcus W Stepp; Daniel W Wilkey; Frederick W Benz; Jian Cai; Michael L Merchant; David W Hein
Journal:  Toxicol Rep       Date:  2022-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.